Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting

临床和临床前环境中铂类和 PARP 抑制剂对生殖系 BRCA 相关胰腺癌的疗效范围

阅读：10

作者：Chani Stossel #, Maria Raitses-Gurevich #, Dikla Atias, Tamar Beller, Yulia Glick Gorman, Sharon Halperin, Eyal Peer, Robert E Denroche, Amy Zhang, Faiyaz Notta, Julie M Wilson, Grainne M O'Kane, Elina Haimov Talmoud, Nora Amison, Michael Schvimer, Seth J Salpeter, Vered Bar, Adi Zundelevich, Itay T

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2023

起止号：

2023 Aug 4;13(8):1826-1843.

doi：

10.1158/2159-8290.CD-22-0412

研究方向：

肿瘤

疾病类型：

胰腺癌

Significance

glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. This article is highlighted in the In This Issue feature, p. 1749.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。